Summary of findings: β‐carotene vs placebo
- Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 24 participantsLow
It is very uncertain whether glycopeptide (vancomycin or teicoplanin) plus aminoglycoside… changes adverse events compared with beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) (very low certainty).
It is very uncertain whether beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) changes adverse events compared with beta‐lactam (ceftriaxone) (very low certainty).
It is very uncertain whether fosfomycin plus imipenem changes adverse events compared with vancomycin (very low certainty).
Partial oral treatment showed no clear difference in adverse events compared with conventional intravenous treatment of endocarditis on the left side… (low certainty).
Comparison 2: 7 days oral amoxicillin + injectable gentamicin showed no clear difference in adverse events compared with 7 days injectable benzylpenicillin + injectable gentamicin (moderate certainty).
Comparison 2: 2 days injectable benzylpenicillin + injectable… showed no clear difference in adverse events compared with 7 days injectable benzylpenicillin + injectable gentamicin (moderate certainty).
Monotherapy showed no clear difference in adverse events compared with combination therapy (moderate certainty).
Carbapenems showed no clear difference in adverse events compared with non‐carbapenems (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Antimicrobial showed no clear difference in minor adverse events compared with placebo or no antibiotics (low certainty).
It is very uncertain whether macrolides changes minor adverse events compared with any other antibiotic (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether antimicrobial changes serious adverse events compared with placebo or no antibiotics (very low certainty).
Azithromycin showed no clear difference in adverse events Men compared with doxycycline (low certainty).